Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer

The purpose of this study was to investigate the effects of combining the phosphotidylinositol-3-kinase (PI3K) inhibitor buparlisib (BKM)120 with the anti-epidermal growth factor receptor (EGFR) agent cetuximab and radiotherapy (RT) on an orthotopic model of head and neck squamous cell carcinoma (HNSCC).

Mots clés

phosphatidylinositol 3-kinase (PIK3CA) head and neck cancer epidermal growth factor receptor (EGFR) radiotherapy targeted therapy

Domaines

Sciences du Vivant [q-bio] Cancer

frédérique penault-llorca : Connectez-vous pour contacter le contributeur

https://hal.science/hal-01675150

Soumis le : jeudi 4 janvier 2018-10:34:07

Dernière modification le : mardi 3 septembre 2024-11:16:04

Dates et versions

hal-01675150 , version 1 (04-01-2018)

Identifiants

HAL Id : hal-01675150 , version 1
DOI : 10.1002/hed.24560
PUBMED : 27507562

Citer

Alexandre Bozec, Nathalie Ebran, Nina Radosevic-Robin, Emmanuel Chamorey, Hedi Ben Yahia, et al.. Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer. Archives of Otorhinolaryngology - Head & Neck Surgery, 2017, 39 (1), pp.151 - 159. ⟨10.1002/hed.24560⟩. ⟨hal-01675150⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

CEA PRES_CLERMONT DRT CEA-UPSAY UNIV-PARIS-SACLAY IMOST UNIV-COTEDAZUR LIST GS-ENGINEERING GS-COMPUTER-SCIENCE GS-SPORT-HUMAN-MOVEMENT

128 Consultations

0 Téléchargements